| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/06/2002 | US6428782 Non-myeloablative tolerogenic treatment |
| 08/06/2002 | US6428780 Modified amino acid |
| 08/06/2002 | US6428324 Vaccine |
| 08/06/2002 | CA2122714C Materials comprising and methods of preparation and use for ribosome-inactivating proteins |
| 08/06/2002 | CA2057010C Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| 08/06/2002 | CA1341381C Yeast hybrid vectors and their use for the production of polypeptides |
| 08/01/2002 | WO2002059609A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | WO2002059604A2 Diagnosis and treatment of multiple sclerosis |
| 08/01/2002 | WO2002059327A2 Sulfatases and methods of use thereof |
| 08/01/2002 | WO2002059319A1 Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen |
| 08/01/2002 | WO2002059318A1 A humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof |
| 08/01/2002 | WO2002059312A2 Cell adhesion proteins |
| 08/01/2002 | WO2002059308A2 Method of diagnosing and treating cartilage disorders |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059292A2 Functional balanced-lethal host-vector systems |
| 08/01/2002 | WO2002059291A2 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | WO2002059286A2 Adenylate cyclases |
| 08/01/2002 | WO2002059264A2 Specific human antibodies for selective cancer therapy |
| 08/01/2002 | WO2002059256A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | WO2002059255A2 Protein-protein interactions in $i(saccharomyces cerevisiae) |
| 08/01/2002 | WO2002059156A2 Therapeutic compounds structurally-linked to bacterial polypeptides |
| 08/01/2002 | WO2002059155A2 Modulation of calcium channel activity |
| 08/01/2002 | WO2002059154A2 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | WO2002059148A2 A method for identification, isolation and production of antigens to a specific pathogen |
| 08/01/2002 | WO2002059146A2 Peptides having affinity for the gp120 viral protein and use thereof |
| 08/01/2002 | WO2002058737A2 Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058728A2 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | WO2002058727A2 Recombinant plasmodium falciparum merozoite protein-1/42 vaccine |
| 08/01/2002 | WO2002058726A1 Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
| 08/01/2002 | WO2002058725A2 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058717A2 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 08/01/2002 | WO2002058714A2 Methods and agents modulating upa/upar activity |
| 08/01/2002 | WO2002058711A1 Therapy-enhancing glucan |
| 08/01/2002 | WO2002058635A2 Nicotine immunogens and antibodies and uses thereof |
| 08/01/2002 | WO2002058628A2 Immunotherapeutic methods for extracorporeal modulation of cd36 and its ligands |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058622A2 Sn-38 lipid complexes and methods of use |
| 08/01/2002 | WO2002058534A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 08/01/2002 | WO2002043651A3 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 08/01/2002 | WO2002042480A3 Modified vaccinia ankara virus variant |
| 08/01/2002 | WO2002040048A3 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis |
| 08/01/2002 | WO2002032923A3 Improved formulations using heat shock/stress protein-peptide complexes |
| 08/01/2002 | WO2002030461A3 Methods for treating disorders of the female reproductive system |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002019986A9 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002004497A3 Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
| 08/01/2002 | WO2002004019A3 Use of strains of the parapox ovis virus against organ fibrosis |
| 08/01/2002 | WO2002002625A3 Novel fibroblast growth factors and nucleic acids encoding same |
| 08/01/2002 | WO2002002137A3 Contraceptive vaccines for pest control |
| 08/01/2002 | WO2001092551A3 Duplexed parvovirus vectors |
| 08/01/2002 | WO2001075114A3 Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001075113A3 Chlamydia myosin heavy chain homolog as antigen, corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001075110A3 Mucin-1 specific binding members and methods of use thereof |
| 08/01/2002 | WO2001074863A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001065934A3 Applications of immune system tolerance to treatment of various diseases |
| 08/01/2002 | WO2001041800A9 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 08/01/2002 | WO2001026672A9 Induction of a strong immune response to a self-tumor associated antigen |
| 08/01/2002 | US20020103343 Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
| 08/01/2002 | US20020103338 Staphylococcus aureus polynucleotides and polypeptides |
| 08/01/2002 | US20020103336 Cloning of chicken anemia dna |
| 08/01/2002 | US20020103212 Pharmaceutical compositions containing anti-fas antibody |
| 08/01/2002 | US20020103151 Methods and compositions for immunomodulation |
| 08/01/2002 | US20020103145 Immunization of infants |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020102729 Formulations for electroporation |
| 08/01/2002 | US20020102723 Nucleotide sequences coding polypeptide for use in diagnosis and treatment of pancreatic defects |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102701 licD1 |
| 08/01/2002 | US20020102679 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 08/01/2002 | US20020102676 Nucleotide sequences coding membrane proteins for use in cancer therapy |
| 08/01/2002 | US20020102666 PSCA: prostate stem cell antigen and uses thereof |
| 08/01/2002 | US20020102658 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 08/01/2002 | US20020102657 Binding protein for use as therapeutic tool in the prevention of Infections disease |
| 08/01/2002 | US20020102652 Polypeptide for use in the diagnosis, prevention and treatment of tumors and autoimmune diseases |
| 08/01/2002 | US20020102651 Novel B7-4 molecules and uses therefor |
| 08/01/2002 | US20020102649 Human transport protein homologs |
| 08/01/2002 | US20020102643 Dorsal tissue affecting factor and compositions |
| 08/01/2002 | US20020102642 Nuclelotide sequences coding preferential protein for use in therapeutic, diagnostic and medical imaging |
| 08/01/2002 | US20020102632 Generating protein complexes for use in the treatment of immunological defects; obtain sample, hydrolyze, incubate with binding protein, recover composition comprising peptides bound to chaperone proteins |
| 08/01/2002 | US20020102619 Heparanase specific molecular probes and their use in research and medical applications |
| 08/01/2002 | US20020102609 Antagonists of HMG1 for treating inflammatory conditions |
| 08/01/2002 | US20020102603 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 08/01/2002 | US20020102602 Polypeptide for use as an antitumor agent |
| 08/01/2002 | US20020102540 Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102288 Flexible applicator for applying oil-in-water emulsion with improved stability |
| 08/01/2002 | US20020102277 Conserved metalloprotease epitopes |
| 08/01/2002 | US20020102276 For diagnosis, therapy and prophylaxis of Neisseria meningitidis infection; vaccine |
| 08/01/2002 | US20020102273 Vaccines to protect animals from disease, particularly from disease caused by protozoan parasites such as Toxoplasma gondii, helminth parasites, ectoparasites, fungi, bacteria, or viruses |
| 08/01/2002 | US20020102270 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 08/01/2002 | US20020102269 Contacting a parental Helicobacter with molecule in biological sample, testing and comparing response to extracellular pH and sensitivity to acidity of parental strain to a strain deficient in UreI; selecting molecule |
| 08/01/2002 | US20020102267 CLASP-5 transmembrane protein |
| 08/01/2002 | US20020102266 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation |
| 08/01/2002 | US20020102263 Diagnosis and treatment of malignant neoplasms |
| 08/01/2002 | US20020102262 For prophhylaxis of Staphylococcus aureus infection |